Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

whtc.com - Thomson Reuters - Swiss pharma industry behind in technology and clinical trials, index shows
Swiss pharma industry behind in technology and clinical trials, index shows
92.7 FM WHTC | Holland –

By Thomson Reuters Nov 4, 2026 | 6:25 AM ZURICH, Nov 4 (Reuters) – Switzerland's pharmaceutical and chemicals industries are slipping behind when it ​comes to technology and ‌clinical trials, a yearly Global Industry…

wsj.com - Lizzy Lawrence - Democratic Sweep Sets Stage for More Pharma Oversight
Democratic Sweep Sets Stage for More Pharma Oversight
Wall Street Journal –

Democrats won big Tuesday on promises to make American life more affordable, particularly health care costs, but the market was unconvinced that policies will dramatically change pharma fortunes. Policy experts expect that Democrats will build on…

wsj.com - Nikkei Rises 0.7%, Led by Auto, Pharma Stocks
Nikkei Rises 0.7%, Led by Auto, Pharma Stocks
Wall Street Journal –

0019 GMT — Japanese stocks are higher after the Democratic sweep of U.S. Congress boosted expectations for a quick end to the Iran conflict, leading to sharply lower oil prices overnight. Auto, pharmaceutical and real-estate stocks are…

chron.com - Royalty Pharma: Q3 Earnings Snapshot
Royalty Pharma: Q3 Earnings Snapshot
Chron –

NEW YORK (AP) — NEW YORK (AP) — Royalty Pharma (RPRX) on Wednesday reported third-quarter earnings of $145 million. The New York-based company said it had profit of 26 cents per share. Earnings, adjusted for non-recurring costs, were…

fool.com - Motley Fool Transcribing - Royalty Pharma (RPRX) Q3 2026 Earnings Call Transcript
Royalty Pharma (RPRX) Q3 2026 Earnings Call Transcript
The Motley Fool –

Chief Executive Officer and Chairman of the Board - Pablo Legorreta EVP, Head of Research and Investments - Marshall Urist EVP, Chief Financial Officer - Terry Coyne Senior Vice President, Head of Investor Relations and Communications - George…

econotimes.com - Celia Rowan - Sun Pharma Shares Slip Below 20-Day EMA, Economic Times Reports
Sun Pharma Shares Slip Below 20-Day EMA, Economic Times Reports
EconoTimes –

A price mismatch on The Economic Times' live page complicates its report that Sun Pharmaceutical Industries Limited shares traded beneath a 20-day EMA in early Thursday trading. At 11:06:05 p.m. EST Wednesday (04:06 UTC Thursday), The Economic…

econotimes.com - Helena Ward - Aurobindo Pharma Sets Quarterly Revenue Record as Q2 Profit Rises 32.5%
Aurobindo Pharma Sets Quarterly Revenue Record as Q2 Profit Rises 32.5%
EconoTimes –

Aurobindo Pharma's revenue from operations reached ₹102.63 billion in the three months ended Sept. 30, 2026, a 23.9% annual increase and a new quarterly high, as consolidated profit after tax rose 32.5%. The company's unaudited results cover…

whtc.com - Thomson Reuters - India's Alembic Pharma profit jumps on strong US sales
India's Alembic Pharma profit jumps on strong US sales
92.7 FM WHTC | Holland –

By Thomson Reuters Nov 4, 2026 | 4:50 AM Nov 4 (Reuters) – India's Alembic Pharmaceuticals posted an 81% rise in second-quarter profit ​on Wednesday, helped by ‌strong sales in the US market, sending its shares surging 20%.

whtc.com - Thomson Reuters - India's Aurobindo Pharma's quarterly profit rises by a third on strong US demand
India's Aurobindo Pharma's quarterly profit rises by a third on strong US demand
92.7 FM WHTC | Holland –

By Thomson Reuters Nov 4, 2026 | 10:27 AM Nov 4 (Reuters) – Indian drugmaker Aurobindo Pharma reported a nearly 33% rise ​in second-quarter profit ‌on Wednesday, led by strong demand and volume gains in its US market. •…

thehindubusinessline.com - BL Hyderabad Bureau - Aurobindo Pharma's Q2 FY27 net up 32% at ₹1124 cr
Aurobindo Pharma's Q2 FY27 net up 32% at ₹1124 cr
The HinduBusinessLine –

Updated - November 04, 2026 at 08:57 PM. Aurobindo Phama's consolidated net profit increased 32.5 per cent at ₹1,124 crore in the second quarter of the current financial year ended September 30, 2026, compared to ₹848 crore in the…

marketbeat.com - Nuvectis Pharma Q3 Earnings Call Highlights
Nuvectis Pharma Q3 Earnings Call Highlights
MarketBeat –

Nuvectis Pharma NASDAQ: NVCT said its third quarter marked a strategic shift into late-stage development following a licensing agreement with Haisco for ex-China rights to two drug candidates: ciprocopan, also known as NXP100, and NXP200. Chairman…

thehindubusinessline.com - BL Mumbai Bureau - Ennature Bio Pharma lists on NSE and BSE, targets branded nutraceuticals growth
Ennature Bio Pharma lists on NSE and BSE, targets branded nutraceuticals growth
The HinduBusinessLine –

Updated - November 04, 2026 at 05:38 PM. Ennature Bio Pharma Limited made its stock market debut on the National Stock Exchange and BSE on Wednesday, November 4, 2026. The company, a demerged division of India Glycols Limited. The company reported…

marketbeat.com - Astellas Pharma (OTCMKTS:ALPMY) Issues Quarterly Earnings Results
Astellas Pharma (OTCMKTS:ALPMY) Issues Quarterly Earnings Results
MarketBeat –

Astellas Pharma (OTCMKTS:ALPMY - Get Free Report) posted its quarterly earnings data on Wednesday. The company reported $0.35 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.41 by ($0.06), Zacks reports. Astellas…

wsj.com - Kristin Broughton - A CFO's Superpower in a Midterm Election: Planning for Multiple Scenarios
A CFO's Superpower in a Midterm Election: Planning for Multiple Scenarios
Wall Street Journal –

Good morning. Chief financial officers typically steer clear of politics. But in the lead-up to a big U.S election, such as yesterday's vote, they're also in their element, scenario-planning for possible outcomes. For many companies, Election Day…

marketbeat.com - Urogen Pharma (NASDAQ:URGN) Shares Down 16.3% on Disappointing Earnings
Urogen Pharma (NASDAQ:URGN) Shares Down 16.3% on Disappointing Earnings
MarketBeat –

Urogen Pharma (NASDAQ:URGN - Get Free Report)'s stock price dropped 16.3% on Wednesday following a dissappointing earnings announcement. The stock traded as low as $29.35 and last traded at $28.80. 252,768 shares changed hands during trading, a…

Receive a Daily briefing on Pharma Industry News

Get Started